Short answer
Amneal Pharmaceuticals, Inc. (AMRX) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $863M (up 10.0% year over year) with net income of −$22M.
Q3 2026 key financials · XBRL
- Revenue
- $863M
- +10.0% YoY · +8.4% QoQ
- Net income
- −$22M
- −1015.8% YoY · −137.6% QoQ
- Operating margin
- 11.1%
- Gross margin
- 38.7%
- EPS (diluted)
- −$0.08
- −144.4% QoQ
Source: XBRL data from the Amneal Pharmaceuticals, Inc. (AMRX) Q3 2026 10-Q on SEC EDGAR. USD.
Amneal Pharmaceuticals, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $862.7M, up 10.0% YoY from $784.5M
- Gross margin 38.7% vs 34.9%; operating income $95.4M vs $70.3M
- Specialty strongest: revenue $150.3M, up 20.0%; gross margin 69.2% vs 41.1%
- AvKARE weakest: revenue $165.3M, down 16.7%; operating income $17.4M, down 35.7%
- Operating cash flow $50.3M year-to-date vs $209.7M; Kashiv acquisition funding drove $476.7M net borrowings
- Tariff uncertainty and potential future generic-drug tariffs could increase costs and pressure margins; 2026 capital expenditures estimated at $150.0M
Risk Factors
- New acquisition risk: Kashiv integration and biosimilar execution following $421.0 million cash consideration and 28.9 million shares issued
- Regulatory risk: proposed generic-drug tariffs could reach 100% after July 31, 2028 and 200% thereafter
- Legal risk: $8.0 million government-investigation charge recognized during the quarter
- Operational risk: severe rain temporarily suspended an India facility and caused $5.4 million property and inventory charges
- Financial risk: Kashiv financing increased revolver borrowings to $180.0 million and added $350.0 million Term Loan Due 2032 borrowings
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Amneal Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.